Brought to you by 
FOPO nets $282mm for Amicus
23 Feb 2018
Executive Summary
Amicus Therapeutics Inc. (therapies for rare metabolic conditions) netted $282mm in its follow-on public offering of 19.35mm common shares at $15.50. The company will use some of the proceeds for global commercialization of migalastat for Fabry's disease, to invest in manufacturing capabilities for its Phase II Pompe disease candidate ATB200, and for additional R&D and commercial activities.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FOPO nets $282mm for Amicus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice